Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2014

Conditions
HypertensionDiabetes Type 2
Interventions
DRUG

Sitagliptin (DPP4 inhibitor)

Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions

DRUG

Substance P,

Substance P intra-brachial artery (2,4,8 pmol/min)

DRUG

bradykinin

bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)

DRUG

enalaprilat (ACE inhibitor)

intra-brachial artery(0.33 µg/min per 100 mL forearm volume)

DRUG

Glucagon-like peptide 1

intra-brachial artery (0.45-3.60 pmol/min)

DRUG

brain natriuretic peptide

Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)

Trial Locations (1)

37232

Vanderbilt University- General Clinic Research Center, Nashville

All Listed Sponsors
lead

Vanderbilt University

OTHER

NCT01413542 - Pharmacogenetics of Ace Inhibitor-Associated Angioedema | Biotech Hunter | Biotech Hunter